香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （ 於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 2025年第三季度報告 下文為上海復星醫藥（ 集團 ）股份有限公司（「本公司」，連同其附屬公司，統稱「本集團」）截 至2025年9月30日止三個月（「報告期」、「本報告期」）之2025年第三季度報告（「2025年第三季 度報告」）。該財務報告乃按照中國企業會計準則編製，且未經審計。 承董事會命 上海復星醫藥（集團）股份有限公司 董事長 陳玉卿 中國，上海 2025年10月28日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-168 ●召开时间：2025 年 11 月 20 日(星期四)13:00-14:00 ●召开方式：网络互动 ●互动网址：上证路演中心（https://roadshow.sseinfo.com） ●投资者可于 2025 年 11 月 13 日(星期四)至 11 月 19 日(星期三)16:00 期间登 录上证路演中心网站首页点击"提问预征集"栏目进行提问，或将问题以电子邮件 形式发送至本公司投资者关系邮箱 ir@fosunpharma.com。本公司将于业绩说明会上 就投资者普遍关注的问题进行回答。 上海复星医药（集团）股份有限公司（以下简称"本公司"）于 2025 年 10 月 29 日披露 2025 年第三季度报告。为便于广大投资者更全面深入地了解本集团（即 本公司及控股子公司/单位，下同）2025 年前三季度的业绩和经营情况，兹定于 2025 年 11 月 20 日 13:00-14:00 召开本公司 2025 年第三季度业绩说明会（以下简称"本 次业绩说明会"），与投资者进行交流。现将有关事项公告如下： 一、业绩说明会类型 本次业绩说明会以 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-167 上海复星医药（集团）股份有限公司 关于调整 2025 年部分日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示（简称同正文） ●本次调整已经本公司第十届董事会第十三次会议审议通过，无需提请股东会 批准。 ●本次调整系基于业务实际开展需要而作出，所涉交易系本集团与关联/连方以 自愿、平等、互利、公允为原则开展，定价依据以市场价格为基础确定；本次调整 不存在损害本公司及非关联/连股东利益的情况，不影响本集团的独立性。 一、本次调整概述 | | | | 2025 年 1 至 9 月 | 2025 上限金额 | 年预计 | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 交易 | 关联/ | 交易内容 | 实际发生 | | | 本次 | 调整 | | 类别 | 连方 | | 金额 | 本次 调整前 | 本次 调整后 | 调整额 | 原因 | | | | | (未经审计 ...

上海复星医药（集团）股份有限公司 证券代码：600196 股票简称：复星医药 编号：临 2025-166 关于拟筹划控股子公司分拆上市的提示性公告 ●本公司2025年10月28日召开的第十届董事会第十三次会议，已审议通过《关 于筹划控股子公司复星安特金（成都）生物制药有限公司于香港联合交易所有限公 司上市的议案》，同意授权本公司及控股子公司复星安特金管理层或其授权人士启 动复星安特金于香港联交所上市的前期筹划工作。具体分拆上市方案将基于可行性 论证结果进一步拟订，并另行提请本公司董事会、股东会审议。 ●特别风险提示： 1、截至本公告日期，建议分拆上市尚处于前期初步论证阶段（论证内容包括但 不限于相应的上市条件是否满足），因此尚无具体方案，建议分拆上市存在重大不 确定性。 2、建议分拆上市尚需满足多项条件方可实施，包括但不限于取得本公司董事会 会及股东会对相关分拆上市方案的批准、完成中国证券监督管理委员会备案及上市 地相关监管机构的核准程序，以及获得相关法律法规所要求的其他可能涉及的批准 等。建议分拆上市能否获得上述批准或核准以及最终获得相关批准或核准的时间均 存在不确定性。 本公司董事会及全体董事保证本公告内 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-169 上海复星医药（集团）股份有限公司 关于参与设立私募股权投资基金的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示 ●投资标的及金额： 控股子公司复星医药产业拟作为 LP 与其他 11 方投资人共同出资设立目标基金。 目标基金计划募集资金人民币 100,000 万元，其中：复星医药产业拟现金出资人民 币 10,000 万元认缴目标基金中的等值财产份额。目标基金设立后，将成为本公司之 联营企业。 ●根据上证所《上市规则》，本次投资不构成关联交易。 ●本次投资不构成《上市公司重大资产重组管理办法》规定的重大资产重组。 3、目标基金拟投资的项目可能受到（包括但不限于）政策法规、经济环境、行 业周期、市场变化、投资标的经营情况等诸多因素的影响，且投资周期较长，可能 存在不能实现预期收益、不能及时有效退出等风险，且无保本及最低收益承诺。 1 ●本次投资无需提请本公司董事会及股东会批准。 ●特别风险提示： 1、截至本公告日期，目标基金尚处于筹备和募集阶 ...

证券代码：600196 股票简称：复星医药 编号：临 2025-165 上海复星医药（集团）股份有限公司 第十届董事会第十三次会议（定期会议）决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海复星医药（集团）股份有限公司（以下简称"本公司"）第十届董事会第 十三次会议（定期会议）于 2025 年 10 月 28 日在上海市宜山路 1289 号会议室以现 场与通讯（视频会议）相结合方式召开，应到会董事 11 人、实到会董事 11 人。会 议由本公司执行董事、董事长陈玉卿先生主持。本次会议的召开符合《中华人民共 和国公司法》、其他有关法律法规和《上海复星医药（集团）股份有限公司章程》 的规定。会议审议并达成如下决议： 一、审议通过本集团 12025 年第三季度报告。 同意按中国境内相关法律法规编制的本集团 2025 年第三季度报告。 表决结果：同意 11 票，反对 0 票，弃权 0 票。 本议案在提交董事会审议前，已经审计委员会事前认可。 2025 年第三季度报告详见上海证券交易所网站（https://www.sse. ...

Core Viewpoint - Fosun Pharma reported a decline in revenue for the third quarter, while showing an increase in net profit year-on-year [1] Financial Performance - The company's revenue for the third quarter was 9.879 billion yuan, a year-on-year decrease of 5.46% [1] - The net profit attributable to shareholders for the third quarter was 821 million yuan, a year-on-year increase of 4.52% [1] - For the first three quarters, the total revenue was 29.393 billion yuan, a year-on-year decrease of 4.91% [1] - The net profit attributable to shareholders for the first three quarters was 2.523 billion yuan, a year-on-year increase of 25.50% [1]

Financial Performance - The company's operating revenue for Q3 2025 was approximately ¥9.88 billion, a decrease of 5.46% compared to the same period last year[6]. - The total profit for the quarter was approximately ¥1.12 billion, down 1.89% year-on-year, while the net profit attributable to shareholders increased by 4.52% to approximately ¥821.33 million[6][7]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was approximately ¥612.46 million, reflecting a year-on-year increase of 5.20%[9]. - Cash flow from operating activities for the quarter was approximately ¥1.25 billion, an increase of 15.57% compared to the same period last year[6]. - The basic and diluted earnings per share for the quarter were both ¥0.31, representing a year-on-year increase of 6.90%[6]. - For the first three quarters of 2025, the company achieved operating revenue of CNY 29.393 billion, a decrease compared to the same period last year[18]. - The net profit attributable to shareholders for the first three quarters of 2025 was CNY 2.523 billion, with a net profit of CNY 1.573 billion after deducting non-recurring gains and losses[18]. - Total operating revenue for the first three quarters of 2025 was CNY 29.39 billion, a decrease of 4.9% compared to CNY 30.91 billion in the same period of 2024[37]. - Net profit for the first three quarters of 2025 reached CNY 3.06 billion, an increase of 21.3% from CNY 2.52 billion in the first three quarters of 2024[37]. - Total comprehensive income for the period attributable to the parent company was CNY 2,242,462,807.32, an increase from CNY 1,833,394,697.38 in the same period last year, representing a growth of approximately 22.3%[38]. - Basic and diluted earnings per share increased to CNY 0.95 from CNY 0.75, reflecting a growth of 26.7% year-over-year[38]. Assets and Liabilities - The total assets of the company as of September 30, 2025, were approximately ¥118.12 billion, a slight increase of 0.56% from the end of the previous year[6]. - The equity attributable to shareholders was approximately ¥48.03 billion, up 1.62% from the end of the previous year[6]. - The company's total assets as of September 30, 2025, amounted to CNY 118.12 billion, slightly up from CNY 117.46 billion at the end of 2024[36]. - Total liabilities decreased to CNY 57.31 billion from CNY 57.53 billion year-over-year[36]. - The company’s long-term equity investments increased to CNY 26.38 billion from CNY 24.69 billion, reflecting a growth of 6.8%[36]. - The company’s total equity increased to CNY 60.81 billion from CNY 59.93 billion, indicating a growth of 1.5% year-over-year[36]. - Total liabilities increased to CNY 15,795,860,646.14 from CNY 14,947,230,943.39, representing an increase of approximately 5.7%[44]. - The total equity attributable to shareholders decreased to CNY 35,567,203,718.02 from CNY 35,728,698,458.71, a decline of about 0.45%[44]. Research and Development - Research and development expenses for the first three quarters of 2025 totaled CNY 2.730 billion, an increase of 3.08% year-on-year[19]. - The company’s total R&D investment for the first three quarters of 2025 was CNY 3.998 billion, reflecting a growth of 2.12% year-on-year[19]. - In Q3 2025, R&D expenses reached CNY 1.013 billion, marking a significant increase of 28.81% year-on-year[19]. - The company continues to focus on innovative drugs and high-end medical devices, aiming to optimize asset and financial structures through lean operations[18]. - The company’s innovative drug pipeline continues to expand, with multiple products in various stages of clinical trials and regulatory approvals[26]. - The company aims to enhance treatment options for patients with advanced cancers through its ongoing research and development efforts[21]. Shareholder Information - The controlling shareholder, Fosun High Technology, held a total of 961.424 million shares, accounting for approximately 36.00% of the total share capital at the end of the reporting period[16]. - The top ten shareholders collectively held 1.5 billion shares, with Fosun High Technology being the largest shareholder[15]. - The company completed the repurchase of 14,228,552 A shares, accounting for approximately 0.5328% of the total share capital, with a total repurchase amount of approximately RMB 348.36 million, at an average price of RMB 24.48 per share[30]. - The company repurchased 3,410,500 H shares, representing about 0.1277% of the total share capital, with a total repurchase amount of approximately HKD 47.84 million, at an average price of HKD 14.03 per share[31]. - The company approved an A-share stock option incentive plan, granting up to 5,726,100 A-share options, with the first grant not exceeding 4,580,900 options[33]. - The company approved an H-share restricted stock unit plan, granting up to 13,370,500 H-share restricted stock units, with the first grant not exceeding 10,696,400 units[34]. Regulatory Approvals and Product Development - The company received approval for a new indication of its innovative small molecule CDK4/6 inhibitor, FCN-437c, for the treatment of HR-positive, HER2-negative locally advanced or metastatic breast cancer in China[21]. - The company’s HLX14 injection was approved by the FDA and the European Commission, covering all indications previously approved for the original product, making it the first domestically produced HLX14 to gain overseas approval[22]. - The company’s innovative PD-1 inhibitor, SRL-172, achieved its primary endpoint in a Phase III clinical study for gastric cancer, supporting early market application[23]. - The company established a nuclear medicine platform, Xingrui Jingxuan, to develop integrated diagnostic and therapeutic nuclear medicine products targeting the oncology field[24]. - The company submitted a registration application for FKC889 injection for the treatment of relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) in adults, which was accepted by the National Medical Products Administration in September 2025[22]. - The company’s HLX43 injection received orphan drug designation from the FDA for the treatment of thymic epithelial tumors, aiding its subsequent development and commercialization in the U.S.[23]. - The company is preparing clinical trials for Ga[68Ga]PSMA-0057 and Lu[177Lu]PSMA-0057 injections as part of its nuclear medicine product pipeline[24]. - The company has initiated clinical trials for HLX79, a treatment for active renal glomerulonephritis, and HLX43, targeting advanced non-small cell lung cancer (NSCLC) in the U.S.[28].

Group 1: Market Performance - The family doctor concept index rose by 1.38%, ranking 6th among concept sectors, with 17 stocks increasing in value [1] - Notable gainers included Haixia Innovation, which hit a 20% limit up, and other stocks like Heren Technology, ST Yinjian, and Zhujiang Shares, which rose by 5.00%, 3.88%, and 3.52% respectively [1] - The biggest decliners were Weining Health, Fosun Pharma, and Focus Technology, which fell by 2.85%, 2.05%, and 1.21% respectively [1] Group 2: Capital Flow - The family doctor concept sector saw a net inflow of 163 million yuan, with 10 stocks receiving net inflows, and 7 stocks attracting over 10 million yuan [2] - The top stock for net inflow was Keda Xunfei, with a net inflow of 155 million yuan, followed by China Ping An, Meian Health, and Haixia Innovation with net inflows of 142 million yuan, 50.97 million yuan, and 26.50 million yuan respectively [2] - In terms of capital inflow ratios, ST Yinjian, Huaping Shares, and Zhujiang Shares led with net inflow rates of 15.37%, 10.55%, and 10.31% respectively [3] Group 3: Individual Stock Performance - Keda Xunfei had a daily increase of 1.46% with a turnover rate of 3.29% and a net capital flow of 154.67 million yuan [3] - China Ping An showed a minimal increase of 0.02% with a net capital flow of 141.56 million yuan [3] - Haixia Innovation experienced a significant rise of 19.97% with a turnover rate of 20.34% and a net capital flow of 26.50 million yuan [3]

Core Viewpoint - Fosun Pharma reported a decline in revenue for Q3 2025, primarily due to the impact of centralized drug procurement, while net profit showed a positive growth trend [1] Financial Performance - Q3 2025 revenue reached 9.879 billion yuan, a year-on-year decrease of 5.46% [1] - Net profit attributable to shareholders for Q3 2025 was 821 million yuan, an increase of 4.52% year-on-year [1] - For the first three quarters of 2025, total revenue was 29.393 billion yuan, down 4.91% year-on-year [1] - Net profit attributable to shareholders for the first three quarters was 2.523 billion yuan, reflecting a year-on-year growth of 25.50% [1] Market Impact - The decline in revenue for the first three quarters and Q3 was mainly influenced by the continuation of centralized drug procurement and the initiation of such programs in certain regions [1] - Despite the revenue decline, the income from innovative drugs showed steady growth during the same period [1]